Sclerosing rhabdomyosarcoma (ScRMS) and spindle cell rhabdomyosarcoma (SRMS) have been recently reclassified as a stand-alone pathologic entity, separate from embryonal RMS. Genetically, a subset of the congenital cases display NCOA2 gene rearrangements, whereas tumors occurring in older children or adults harbor MYOD1 gene mutations with or without coexisting PIK3CA mutations. Despite these recent advances, a significant number of tumors lack known genetic alterations. In this study we sought to investigate a large group of pediatric SRMS/ScRMS, spanning a diverse clinical and pathologic spectrum, by using a combined fluorescence in situ hybridization, targeted DNA, and whole-transcriptome sequencing methodology for a more definitive molecular classification. A total of 26 SRMS and ScRMS cases were selected from the 2 participating institutions for the molecular analysis. Ten of the 11 congenital/infantile SRMS showed recurrent fusion genes: with novel VGLL2 rearrangements seen in 7 (63%), including VGLL2-CITED2 fusion in 4 and VGLL2-NCOA2 in 2 cases. Three (27%) cases harbored the previously described NCOA2 gene fusions, including TEAD1-NCOA2 in 2 and SRF-NCOA2 in 1. All fusion-positive congenital/infantile SRMS patients with available long-term follow-up were alive and well, none developing distant metastases. Among the remaining 15 SRMS patients older than 1 year, 10 (67%) showed MYOD1 L122R mutations, most of them following a fatal outcome despite an aggressive multimodality treatment. All 4 cases harboring coexisting MYOD1/PIK3CA mutations shared sclerosing morphology. All 5 fusion/mutation-negative SRMS cases presented as intra-abdominal or paratesticular lesions.
R habdomyosarcomas (RMSs) are the most common soft tissue sarcomas in children, accounting for 5% to 8% of all pediatric malignancies. Traditionally, RMSs have been divided into 2 clinicopathologic groups: embryonal RMS (ERMS), occurring in younger patients, histologically reminiscent to fetal skeletal muscle, and alveolar RMS (ARMS), often diagnosed in older children, being characterized by a monomorphic round cell cytology, with a variable alveolar pattern and carrying recurrent translocations, a t(2;13)(q35;q14) or t(1;13)(p36;q14) in about 80% of cases. 1 Whereas ARMSs follow a highly aggressive course, the prognosis of ERMS has significantly improved in recent years with an overall survival of 70% at 5 years for patients presenting with localized disease. 2, 3 The spindle cell variant of rhabdomyosarcoma (SRMS) is an uncommon subtype of RMS that was initially grouped under ERMS, having predilection for paratesticular and head and neck sites and being associated with a more favorable behavior in children. 4, 5 A subset of SRMSs display areas of prominent hyaline sclerosis and a pseudovascular growth pattern, suggesting morphologic overlap with the even less common sclerosing RMS (ScRMS). ScRMS is characterized by cords or microalveolar patterns, embedded in a prominent sclerotic or hyalinized stroma. 6, 7 As both SRMS and ScRMS have similar clinical presentations and overlapping histologic features, it was suggested that they might represent a morphologic spectrum, with possibly shared pathogenesis. 6, 8, 9 Subsequently, the latest World Health Organization (WHO) classification merged these 2 entities into a single pathologic entity, distinct from ERMS and ARMS. 10 The recent evidence of recurrent MYOD1 gene mutations present in both SRMS and ScRMS supports the unifying concept proposed by WHO 2013 on morphologic grounds alone. 11 However, despite these genetic advances and refinement in classification, the heterogeneity of this subgroup of RMS even within the pediatric population has become apparent, as evidenced by important genetic and clinical characteristics being age-dependent. Notably, recurrent NCOA2 gene rearrangements have been identified in a subset of congenital/infantile SRMS associated with a favorable clinical course. 12 In contrast, all 4 pediatric patients with SRMS/ScRMS carrying MYOD1 mutations followed a highly aggressive course, similar to the adult patients. 11 In this study we further expand our investigation of pediatric SRMS and ScRMS in a large cohort of different clinical presentations, using a combined molecular approach, including next-generation paired-end RNA sequencing for novel fusion discovery, mutation analysis, and fluorescence in situ hybridization (FISH), for a better molecular subclassification and risk factor stratification in the pediatric age group.
MATERIALS AND METHODS

Patient Selection
Archival material from pediatric patients with diagnosis of SRMS or ScRMS was retrieved from the Institutional and consultation files of the Departments of Pathology of the University of Padua and Memorial Sloan Kettering Cancer Center. Twenty-six cases were identified, and the diagnosis was confirmed on the basis of histologic features and positive immunohistochemical reactivity for desmin and myogenin. All cases were screened at diagnosis for PAX3/7-FOXO1 gene fusions either by reverse transcription polymerase chain reaction (RT-PCR) or FISH and were negative. All cases had archival formalin-fixed paraffin-embedded material for further molecular testing. In addition, 6 cases had adequate frozen tissue material, 4 of these being subjected to paired-end RNA sequencing, and 2 were previously analyzed by 5 0 RACE. 12 Three cases were previously included in the study by Mosquera et al 12 and 4 cases by Agaram et al 11 (Table 1 ). The study was approved by the Institutional Review Board at each institution.
Clinicopathologic Features
The clinical data of the 26 patients (11 boys and 15 girls) with an overall age range of 0 to 17 years (median 3 y, mean 5.5 y) are summarized in Table 1 . Eleven of these patients were diagnosed at birth (congenital) or within 1 year of age (infantile), with equal sex distribution. All except 1 of the congenital/infantile cases were located in the trunk: back/paravertebral areas, 5; chest wall, 3; posterior neck/paraspinal, 2. Only 1 occurred in the limb soft tissues (calf). The remaining 15 patients, 9 boys and 6 girls, were diagnosed in older children, with a mean age of 9.4 years (range 2 to 17 y, median 9.5 y). The anatomic distribution for this latter subgroup was more variable, with 5 intra-abdominal/ paratesticular, 3 cases in the trunk (paraspinal, paravertebral, back), 4 in the head and neck (infratemporal, cheek, orbit), 2 in the buttock, and 1 in the thigh.
Hematoxylin and eosin-stained slides from all cases were reviewed by 2 sarcoma pathologists (R.A., C.R.A.). The diagnosis of SRMS was defined according to the current criteria proposed by WHO 2013 classification, when there was a predominant spindle cell morphology, with only focal if any rhabdomyoblastic differentiation and absent or minimal nuclear pleomorphism. ScRMS was defined as tumors with variable cellularity, composed of spindle cells or round cells arranged in a pseudovascular/pseudoalveolar or tubular-like pattern, embedded in a hyalinizing stroma. Positive immunostaining for desmin and, at least focally, for myogenin were required for diagnosis.
A detailed morphologic examination was carried out in each case, recording the predominant growth pattern (herring-bone, fascicular, fibromatosis-like), amount and quality of cytoplasm, degree of cytologic atypia (nuclear hyperchromasia, type of chromatin degree of nuclear pleomorphism), mitotic rate, and type of stromal component. On the basis of some of these features the tumors were also defined as resembling other mesenchymal tumors, such as fibrosarcoma-like, leiomyosarcoma-like, and fibromatosislike. Clinicopathologic features, including size, location, management, and follow-up, were obtained from the medical records for all cases. Subsequently, the histologic features were compared with the results of cytogenetic and molecular characterization.
RNA Sequencing
Four cases were analyzed by RNA sequencing (SRMS #1, 6, 7, 17) . Total RNA was prepared for RNA sequencing in accordance with the standard Illumina mRNA sample preparation protocol (Illumina). Briefly, mRNA was isolated with oligo(dT) magnetic beads from total RNA (2 mg). The mRNA was fragmented by incubation at 941C for 2.5 minutes in fragmentation buffer (Illumina). To reduce the inclusion of artifact chimeric transcripts into the sequencing library, an additional gel size-selection step was introduced before the adapter ligation step. 13 The adaptorligated library was then enriched by PCR for 15 cycles and purified. The library was sized and quantified using DNA1000 kit (Agilent) on an Agilent 2100 Bioanalyzer according to the manufacturer's instructions. Paired-end RNA sequencing at read lengths of 50 or 51 bp was performed with the HiSeq 2000 (Illumina). A total of about 60.9 million paired-end reads were generated, corresponding to about 3.1 billion bases. human reference genome (hg19), followed by FusionSeq 16 and TopHat Fusion (ver 0.1.0), 17 respectively, to identify fusion candidates. In the first analysis, mapped reads were converted into Mapped Read Format 18 and analyzed with FusionSeq to identify potential fusion transcripts. An SRF-NCOA2 fusion candidate was identified by Fu-sionSeq in SRMS1 and experimentally validated as previously reported. 12 However, for the additional 3 new cases (SRMS #6, 7, 16) no fusion candidates were identified with this pipeline. We then applied TopHat fusion analysis tool to detect potential gene fusion events with spanning reads >20 bp. In contrast to FusionSeq, To-pHat fusion aligns reads without relying on existing annotation and directly detects individual reads that span the fusion event. This tool proved to be more sensitive to detect small intrachromosomal inversions, which most likely were filtered out by the FusionSeq algorithm. In addition, RNAseq data were analyzed for gene mutation calls. BAM files were generated by STAR alignment, followed by PicardTools (ver 1.130) standard preprocessing, which include marking of duplicate reads, recalibration of base quality scores, and local realignment. MuTect (var 1.15) 19 chori.org). DNA from individual BACs was isolated according to the manufacturer's instructions, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides. Slides were then incubated, washed, and mounted with DAPI in an antifade solution. The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems). A positive score was interpreted when at least 20% of the nuclei showed a break-apart signal. Nuclei with incomplete set of signals were omitted from the score.
Targeted PCR and Sanger Sequencing
Genomic DNA was isolated either from fresh-frozen or archival paraffin tissue, as described previously 21 in all fusion-negative samples. Targeted PCR was performed for the known MYOD1 exon 1 hotspot mutation and PIK3-CA exons 9 and 20 mutations as previously reported. 11 Direct sequencing of PCR products was performed and compared with the NCBI human MYOD1 and PIK3CA gene sequences. For the FGFR4 kinase domain validation we used the following primers: FGFR4 exon 13 Fwd: 5 0 -CAATGTCCCGAC TTCTCCCTCTC-3 0 and FGFR4 exon 13 Rev 5 0 -CAG GTTGATGATGTTCTTGTGTCG-3.
RT-PCR Validation and 5 0 RACE
The VGLL2-CITED2 fusion candidate identified by TopHat fusion was validated by RT-PCR using 1 mg of total RNA and cDNA synthesis by SuperScript III First-Strand Synthesis Kit (Invitrogen, Carlsbad, CA). RT-PCR was performed using the advantage 2 PCR kit (Clonetech, Mountain View, CA) for 33 cycles at a 651C annealing temperature, using the following primers: VGLL2 Intron 3 fwd 5 0 -GTCTGCCCACTGCCCCTTTC-3 0 ; CITED2 Ex2 rev 5 0 -GGTTGAAATACTGGTTGTTGAGC-3 0 . The PCR product was confirmed by agarose gel electrophoresis and then sequenced using the Sanger method. 5 0 RACE was performed in SRMS3 using the SMARTer RACE cDNA Amplification Kit (Clonetech). Reverse transcribed mRNA was initiated by SMARTer II A Oligonucleotide with appropriate 5 0 -RACE CDS Primer A in a 10 mL reaction volume according to the manufacturer's protocol. Primary PCR was performed by Advantage 2 polymerase chain reaction (Clonetech) with the SMARTer RACE Universal Primer A Mix and reverse primer on NCOA2 exon 15 (5 0 -TCCTCCAAAT-CAGACTGCCCCAT-3 0 ). Nested PCR was performed with the SMARTer RACE Nested Universal Primer A and reverse primer on NCOA2 exon 14 (5 0 -GGAACC-CAGCAGCCAGCATC -3 0 ). Amplified PCR products were being cloned by TOPO TA Cloning Kit for Sequencing with One Shot TOP10 Chemically Competent E. coli (Invitrogen). The constructed plasmid DNA was sequenced using the Sanger method.
Western Blotting
Frozen tissue from the 2 samples with VGLL2-CIT-ED2 fusions (SRMS6, SRMS7) and 1 control sample (normal skeletal muscle) were homogenized in Tissue Protein Extraction Reagent (Thermo Scientific, Cat# 78510) supplemented with protease inhibitors. Electrophoresis and immunoblotting were performed on the protein extracts using 30 mg of protein per sample. VGLL2 and b-Actin expression were detected by anti-VGLL2 mouse polyclonal antibody (Abcam, Cat# ab169247) with 1:500 dilution and anti-Actin mouse monoclonal antibody (Cell Signaling, Cat#3700) with 1:1000 dilution, respectively. Following hybridization with the secondary rabbit anti-mouse antibody (Santa Cruz Biotechnology, Santa Cruz, CA; #sc-358923) with 1:5000 dilution, the blots were incubated with Immun-Star horseradish peroxidase luminal/enhancer (Bio-Rad, Hercules, CA) and exposed onto Kodak Biomax MR Film (Eastman Kodak Co., Rochester, NY).
RESULTS
Congenital/Infantile SRMSs Show Recurrent Gene Fusions, Involving VGLL2, SRF, and TEAD1, Critical Transcriptional Regulators of Skeletal Muscle Function
Two of the 3 infantile SRMS tested by TopHat Fusion algorithm showed similar VGLL2-CITED2 gene fusion candidates (SRMS6, SRMS7), which resulted from an intrachromosomal 6 inversion, as the 2 genes have opposite directions of transcription ( Fig. 1A) . RT-PCR confirmed the fusion of VGLL2 intron 3 with CITED2 exon 2 (Fig. 1B) . FISH studies further validated this result in both cases (Fig. 1C ). All the remaining cases were further tested by FISH for VGLL2 gene abnormalities, and 5 additional cases were found to have VGLL2 break/inversion. These 5 cases were further investigated for potential partners and confirmed 2 additional cases with VGLL2-CITED2 fusion (SRMS8, SRMS9), 2 with VGLL2-NCOA2 (SRMS3, SRMS5), and 1 without an identifiable partner (SRMS10). SRMS3 was previously reported by our group as having an NCOA2 gene rearrangement without a proven gene partner. 12 Repeat 5 0 RACE analysis on this case showed the fusion of VGLL2 exon 2 with NCOA2 exon 14 (Fig. 2) , this result being further confirmed by FISH (Fig. 2) . The remaining 3 cases showed SRF-NCOA2 fusions in 1 case (SRMS1) and TEAD1-NCOA2 (SRMS2, SRMS4) in 2 cases. 12 Only 1 tumor (SRMS11) in this group was not associated with gene fusion abnormalities.
Histologically, all 10 fusion-positive infantile SRMS showed a striking resemblance with infantile fibrosarcoma (Fig. 3) , with no morphologic differences among the different fusion types. The lesional cells were monomorphic, with delicate, scant eosinophilic cytoplasm and oval to wavy nuclei, with finely dispersed chromatin, and occasional, inconspicuous nucleoli (Figs. 3A-C). Hyperchromasia was seen in 2 cases as focal and in 1 case as more diffuse (Figs. 3D-H) . Alternating hypocellular areas were present in 4 cases, with collagen bundles interspersed between cells, reminiscent of a desmoid-type fibromatosis (Fig. 3I ). There was no evidence of necrosis. The mitotic rate was typically <5 mitoses/10 HPF, except for SRMS2 with >10/10 HPF. One case (SRMS10) displayed unusual myoid features with a vaguely perivascular pattern of arrangement, mimicking a myofibromatosis. The only fusion-negative tumor, occurring in a 4-month-old baby (SRMS11), showed a more conventional SRMS morphology, characterized by elongated cells with more abundant eosinophilic cytoplasm, scattered large hyperchromatic nuclei, and >10/10 HPF. All tumors showed patchy to diffuse desmin reactivity and scattered, multifocal myogenin and MyoD1 reactivity.
MYOD1-positive S/ScRMSs Occur in Older Children With Predilection in the Trunk and Head and Neck
Among the 15 SRMSs occurring in older children, 10 (67%) had MYOD1 L122R exon 1 mutations, as detected by Sanger sequencing. In all except 2 cases there were MYOD1 L122R homozygous mutations (Table 1) ; both heterozygous MYOD1-mutant cases occurred in female individuals and in the buttock location (2-y-old and 10-y-old). Four of these MYOD1-mutant cases harbored coexisting PIK3CA mutations, 3 being in the exon 10 helical domain (E542V, E545K, and Q546R) and 1 in the exon 21 kinase domain (G1049R). The latter case had available frozen tissue (RMS17) and was studied by RNAseq as initially being diagnosed as an unclassified RMS (possibly representing a fusion-negative solid ARMS). As the TopHat algorithm did not identify any fusion candidates, it was further subjected to mutation detection algorithms, which identified MYOD1 L122R, PIK3CA G1049R, and FGFR4 V548M mutations. These mutations were then confirmed by Sanger sequencing. Upon morphologic re-review, the tumor showed focal areas of sclerosis intermixed within the mostly solid round cell component (Fig. 5 ); thus the case was reclassified as a cellular variant of ScRMS supported by the above mutational profile. In fact all cases with coexisting MYOD1 and PIK3CA mutations were associated with sclerosing histology, being composed of variably cellular, but monomorphic, round to spindle cells embedded in a distinctive hyalinized stroma. The remaining MYOD1-mutant SRMSs displayed a classic morphology, composed of intersecting long fascicles of elongated cells with scant to moderate amount of fibrillary eosinophilic cytoplasms and uniform oval nuclei, reminiscent of leiomyosarcoma ( Fig. 5 ). Rhabdomyoblastic differentiation, although very focal, was often present in the form of scattered rhabdomyoblasts intermixed among the spindle cells. Patchy hyperchromasia was also present, with mostly scattered cytologic atypia. Three tumors showed increased mitotic activity of >10 MF/10 HPF and geographic necrosis.
The remaining 5 cases lacking both fusions and MYOD1 mutations showed overlapping morphologic features with the MYOD1-mutant SRMS ( Supplementary  Fig. 1 , Supplemental Digital Content 2, http://links. lww.com/PAS/A318). In addition, 2 of the cases showed focal myxoid areas. Two cases showed an increased mitotic rate of >10 MF/10 HPF. All cases showed mostly diffuse positivity for desmin, whereas myogenin nuclear staining was found ranging from 5% to 50% of the cells. Additional targeted DNA PCR for the FGFR4 hotspot mutations showed the presence of an FGFR4 exon 13 V550L in SRMS24 (Table 1) .
Fusion-positive Infantile SRMSs Follow a Favorable Clinical Course Compared With the Highly Aggressive Behavior of Older Children With SRMS Harboring MYOD1 Mutations
All patients were treated with preoperative chemotherapy after the diagnosis of SRMS or ScRMS was rendered on the biopsy, except for the 2 paratesticular tumors, which were treated with surgery and subsequent chemotherapy. All 6 fusion-positive congenital/infantile SRMS patients with available long-term follow-up are presently alive and well after a median of 7 years (range, 3 to 13 y). Two patients developed local recurrences, but none developed distant metastases. In contrast, 7 of the 9 MYOD1-mutant RMS patients died of disease, including the 3 cases with sclerosing morphology and coexisting MYOD1/PIK3CA mutations, with a median of 1.5 years (range, 1 to 3 y). Only 1 patient in this group is alive and well after only 1 year of follow-up, and an additional patient is alive with disease after developing a second local recurrence. Among the fusion/MYOD1 mutationnegative subset, 3 of the 4 cases with available follow-up are with no evidence of disease, including the 2 patients with paratesticular and 1 with paraovarian tumors.
DISCUSSION
Despite a relatively homogenous morphologic phenotype, SRMS has emerged as a diverse group of tumors, with different molecular genetic profiles and variable clinical behaviors depending on the age at presentation. In the pediatric population, SRMS was first described by Cavazzana et al 4 in 1992 and subsequently by Leuschner et al 5 a year later as a variant of ERMS, typically occurring in the paratesticular or head and neck region, with histologic features mimicking a leiomyosarcoma. Their clinical behavior appeared to be more favorable compared with classic ERMS. In contrast, Lundgren et al 22 described a small series of 3 SRMSs occurring in children aged 1 to 3 years and displaying a morphology reminiscent of infantile fibrosarcomas (infantile rhabdomyofibrosarcomas), but followed a fatal course in 2 cases. Moreover, in adults, SRMSs also have a predilection for the head and neck region but, unlike the pediatric tumors, seem to follow a more aggressive clinical course. 8, 23, 24 As the evidence for SRMS having distinct clinicopathologic features from ERMS and sharing morphologic features . VGLL2-NCOA2 fusion-positive tumor (SRMS3) showed a highly cellular and hyperchromatic appearance reminiscent of infantile fibrosarcoma with a distinctive hemangiopericytoma-like vascular pattern in the primary tumor (D); in the subsequent 2 local recurrences, 2 years (E) and 5 years (F) later, it had a more sclerosing appearance; latter recurrence showed reactivity for desmin (G) and myogenin (H). In contrast, a VGLL2 rearranged tumor with no identifiable partner showed a more sclerotic background mimicking fibromatosis (SRMS10, I).
with ScRMS became more widely accepted, it led to its reclassification in the latest WHO classification as a stand-alone pathologic entity. 10 From the genetic viewpoint, we have previously described recurrent NCOA2 gene rearrangements in a small subset of SRMS occurring in the infantile/congenital setting. 12 As NCOA2-related fusions were only seen in infants, we speculated that SRMS/ScRMS represents a heterogenous genetic group of tumors among different age groups. Notably, all 3 NCOA2-rearranged SRMSs pursued a favorable clinical course and lacked metastatic potential. The additional 7 fusion-positive infantile SRMSs reported here reinforce our initial results of a very favorable outcome, all patients being without evidence of disease after long-term follow-up.
Herein, we identify novel VGLL2 gene rearrangements located at the 6q22 locus as the most common (64%) genetic abnormality in congenital/infantile SRMS, being fused to either NCOA2 or CITED2 gene partners. This result is not so surprising as VGLL2 is expressed in differentiating somites and branchial arches during embryogenesis and is exclusively expressed in skeletal muscle in the adult. 25 VGLL2 (Vestigial-like 2, a.k.a. VGL2 or VITO1) was identified as a human homolog of a Drosophila protein, Vestigial, a transcriptional coactivator (without DNA-binding sequence) of Scalloped, that contains the TEA domain and is required for wing formation. 26, 27 VGLL2 is a key cofactor of TEF-1 (transcription enhancer factor-1, a.k.a. TEAD1) and MEF2 (myocyte enhancer factor-2) family members regulating , and other subtypes of RMS). Of note, similarly high FGFR4 expression was seen in an adult SRMS, lacking MYOD1, PIK3CA, and FGFR4 mutation (adSRMS1). C, IGV showing MYOD1 L122R mutation with a 42% allele fraction and read coverage of 883 and further confirmed by Sanger sequencing as a heterozygous mutation. D, Bar chart showing overall high expression of MYOD1 mRNA across different RMS and ectomesenchymomas compared with other tumor types, with highest levels in the 2 cases harboring MYOD1 mutations (adSRMS2, SRMS17). muscle-specific gene transcription in skeletal muscle 25, 28 ( Supplementary Fig. 2 , Supplemental Digital Content 3, http://links.lww.com/PAS/A319). In Drosophila, Vgl2 plays a key role in the development and patterning of the wing: its loss results in a failure of wing development, whereas its overexpression leads to the development of ectopic wings. 29 In humans, upon muscle differentiation VGLL2 is upregulated and translocates from the cytoplasm to the nucleus, where it interacts with MEF2 and coactivates TEF-1 and MEF2-dependent muscle-specific promoters. Although VGLL2 alone is not sufficient to initiate myogenic conversion of 10T1/2 fibroblasts in vitro, it enhanced MyoD-mediated myogenic conversion, suggesting that it is a crucial cofactor of the muscle regulatory program. 30 Our results thus implicate a number of critical transcription factors or coactivators involved in skeletal muscle function in the pathogenesis of congenital/infantile SRMS. As most of these cases do not show overt rhabdomyoblastic differentiation morphologically and sometimes display only patchy desmin reactivity, it is intriguing to speculate that their oncogenic role in this tumor is to block skeletal muscle differentiation and maintain a primitive phenotype. Both SRF (serum response factor) and TEAD1 (TEA domain, a.k.a. TEF-1) have been shown to be involved in the control of muscle-specific gene transcription. SRF is highly expressed in skeletal muscle and controls the expression of genes specifically expressed in skeletal muscle (dystrophin, muscle creatine kinase, myoD), including several genes encoding sarcomeric proteins (such as a skeletal actin, myosin light chain, tropomyosin). 31 TEAD1 is constitutively expressed in cardiac and skeletal muscle, acting as a key molecule of muscle development, transactivating multiple target genes involved in cell proliferation and differentiation pathways. 32 In the context of SRMS, these muscle-specific factors (VGLL2, SRF, TEAD1) participate as 5 0 partners in the recurrent translocations and maintain most of their key functional domains within the fusion protein. Thus VGLL2 retains its vestigial motif (Vg), SRF preserves the MADS box and TEAD1 its TEA domain ( Supplementary Fig 2, Supplemental Digital Content 3, http://links.lww.com/PAS/ A319). Interestingly, our RNA sequencing showed that the VGLL2-CITED2 fusion product contained a large intronic sequence of VGLL2 intron 3, which most likely results in a truncated protein. This result is further confirmed by our Western blotting, showing lack of a wild-type VGLL2 protein, compared with normal skeletal muscle, in keeping with a loss of function effect (Fig. 1 ). VGLL2 3 0 fusion partners are either NCOA2 on 8q13.3 or CITED2 on 6q23.3. The exact role of these genes within the fusion remains unclear, as no upregulation of either VGLL2 or CITED2 was noted in the 2 cases with available RNAseq data, suggesting a different role of the fusion transcript other than gene overexpression. CITED2 (Cbp/p300-interacting transactivator with Glu-Asp-rich carboxy-terminal domain, 2) is a cardiac transcription factor, which is essential for heart development. 33 CITED2-deficient mice show cardiac malformations, adrenal agenesis, and neural crest defects. Mutations in this gene were reported to cause cardiac septal defects. 34 Of interest, fusions involving the CITED2 gene have been described recently in a case of high-grade undifferentiated pleomorphic sarcoma, the gene, however, being the 5 0 partner and fused to PRDM10 on 11q24. 35 CITED2 is a nuclear protein that binds closely to the CH1 region of p300 and CBP. In contrast, NCOA2 (nuclear receptor coactivator) is a member of the p160 steroid receptor coactivator gene family. In the COOH-terminal part of NCOA2 there are 2 intrinsic transcriptional activation domains, TAD1 and TAD2, 36, 37 which are responsible for interaction with general transcriptional cointegrators such as CBP and p300. This is intriguing as both CITED2 and NCOA2 maintain their carboxy-terminal in the projected fusion protein structure, thus sharing a CBP/p300 interaction domain, which may be involved in the pathogenesis of SRMS ( Supplementary  Fig. 2 , Supplemental Digital Content 3, http://links. lww.com/PAS/A319).
SRMSs harboring MYOD1 mutations were first described in the adult population, in about 44% of cases tested. 38 Our group subsequently reported their occurrence in both pediatric age group and in sclerosing morphology. 11 In our initial study, all the 4 pediatric MYOD1mutated RMS patients died of the disease at 2-year median follow-up. Interestingly, 2 of the 4 cases showing coexisting PIK3CA helical mutations were associated with sclerosing morphology. 11 Of interest, MYOD1 mutations were also reported in 10% of ERMS, 39 albeit described as having mostly a spindle cell morphology. However, MY-OD1 mutations were not identified in a large genomic study encompassing both fusion-positive ARMS and fusion-negative ERMS. 40 In our expanded cohort of 9 MYOD1-mutant SRMSs, we confirm the initial observations that this genotype is seen in older children (mean age, 10 y), presenting with predilection in the trunk and head and neck area. The presence of MYOD1 mutations is associated with a highly aggressive course despite multimodality treatment, with 7/9 children with available follow-up dying of disease within 1 year of diagnosis. Once again the coexisting PIK3CA mutation was associated with sclerosing morphology. Of note, 1 of the ScRMSs tested by RNAseq showed 3 coexisting mutations: MYOD1 L122R, kinase domain PIK3CA G1049R, and kinase domain FGFR4 V548M. Although previous kinase domain mutations in FGFR4 have been reported in about 6% to 7% of RMS, 40, 41 mostly in ERMS, 42 this case appears to be the first report of FGFR4 mutations in an SRMS/ScRMS. The RNAseq in this case showed high upregulation of FGRF4 mRNA (Fig. 4) . Furthermore, the association of these 3 activating mutations in 1 single case might explain the highly undifferentiated phenotype noted, reminiscent of a fusion-negative solid ARMS. Only in retrospect, after the mutation profile became available, the case was reclassified as a cellular variant of ScRMS due to the presence of focal areas of sclerosis. This case raises the question of whether a subset of the so-called fusion-negative solid ARMS represents in fact cellular/solid-variants of ScRMS. Indeed a recent re-review of the ARMS in patients enrolled in the Children Oncology Group (COG) studies from 1999 to 2005 resulted in the reclassification of 30% of cases, either into ERMS with a so-called "dense pattern" or ScRMS. 43 It also raises the possibility that accumulating secondary oncogenic mutations, possibly synergistic to the MYOD1 initiating event, are responsible for blocking differentiation and associated fatal outcome. SRMS with MYOD1 mutations showed significantly higher upregulation of MYOD1 mRNA, on the basis of 2 cases with available RNAseq data, either occurring in an adult (adSRMS2) or in a child (SRMS17), compared with other RMS subtypes (Fig. 4) .
Despite our detailed molecular investigation, there was a remaining third group of tumors, lacking recurrent genetic abnormalities and presenting with predilection in the genito-urinary or intra-abdominal location. Although the data are quite limited for definitive conclusions, these patients appeared to follow a more favorable course compared with the MYOD1-mutant cases and might either represent a third genetic group of SRMS or may be more closely related to the ERMS. Only 1 of these 5 cases showed FGFR4 V550L mutations, as previously documented in ERMS. 41 In conclusion, despite a relatively similar histomorphology, pediatric SRMS is a heterogenous disease genetically as well as clinically. Our study identifies 3 distinct molecular subsets of SRMS/ScRMS within the pediatric age group. First, tumors presenting at birth or within 1 year of age occur with predilection in the trunk and are associated with recurrent gene fusions, involving critical transcriptional activators of muscle-specific genes, such as VGLL2, TEAD1, and SRF. Most importantly, these patients follow a favorable clinical outcome, lacking metastatic potential, all being alive and well at long-term follow-up. This fusion-positive infantile SRMS group appears closely reminiscent to the behavior of ETV6-NTRK3-positive infantile fibrosarcomas and militate against their classification as a "high-grade neoplasm." Second, our findings further show that pediatric MY-OD1-mutant SRMSs, with or without accompanying PIK3CA mutations, follow a highly aggressive course with high mortality despite multimodality therapy. In fact, MYOD1 mutation was the most common genetic abnormality in pediatric SRMS, occurring in 67% of children beyond 1 year of age, and can be used as a molecular diagnostic test to stratify these high-risk patients. Third, despite our detailed molecular investigation, there is a remaining group lacking gene fusions or MY-OD1 mutations often presenting intra-abdominally or in the genito-urinary area. This latter subset seems to follow a favorable clinical course; however, the data remain limited to determine whether it represents a separate molecular group or has a closer relationship to the more common ERMS in this location.
